Bazedoxifene + Estrogens for Atherosclerosis (APPT Trial)

"According to the official clinicaltrials.gov page, applications for this trial are still being accepted. This study was initially announced on April 13th 2021 and has since been updated as of June 30th 2022."

"This investigation is recruiting up to 400 individuals with atherogenesis who are between 45 and 59 years old."

"With Phase 2 clinical data confirming its safety, our team at Power assigned Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg a score of 2 on the 1-3 scale. No efficacy studies have been conducted yet."

"Currently, Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg is being investigated in 15 clinical trials with one of them in the final stage of evaluation. Most studies are found in League City, Texas while 31 sites across the country have opened up recruitment for this medication."

"To be considered for this clinical trial, prospective participants must fall within the age range of 45-59. There are 26 studies recruiting patients under 18 years old and 662 aiming to enroll persons that have exceeded 65 years of life."

"Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg is a viable treatment for premature menopause, female castration, and vasomotor system issues."

"Affirmative. According to the clinicaltrials.gov website, recruitment is still open for this trial which was first posted on April 13th 2021 and updated most recently on June 30th 2022. The researchers are looking to sign up 400 individuals at a single site."